The Dana-Farber Cancer Institute has identified molecular glue degraders comprising a cereblon (CRBN) ubiquitin ligase-binding moiety covalently bound to a zinc finger protein Helios (IKZF2) ligand reported to be useful for the treatment of cancer.
Aerie Pharmaceuticals Inc. has divulged dual-acting compounds consisting of a glucocorticoid moiety and a Rho kinase 1 (ROCK) inhibitor bound through a linker. They are reported to be useful for the treatment of eye disorders.
Suzhou Suncadia Biopharmaceuticals Co. Ltd. and Jiangsu Hengrui Medicine Co. Ltd. have synthesized isoquinolone compounds acting as phosphodiesterase PDE3A and/or PDE4 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), sepsis, nephritis, diabetes, allergic rhinitis, allergic conjunctivitis and rheumatic diseases.
Medshine Discovery Inc. has disclosed derivatives of a six-membered heteroaromatic urea ring acting as soluble guanylate cyclase (sGC) activators reported to be useful for the treatment of diabetic and hypertensive nephropathy.